Medscape September 11, 2024
Edited by Shrabasti Bhattacharya

TOPLINE:

MADRID — Elevated interleukin (IL) 6 levels are associated with an increased risk for obesity-related cancers in patients newly diagnosed with type 2 diabetes (T2D), potentially enabling the identification of higher-risk individuals through a simple blood test.

METHODOLOGY:

  • T2D is associated with an increased risk for obesity-related cancers, including breast, renal, uterine, thyroid, ovarian, and gastrointestinal cancers, as well as multiple myeloma, possibly because of chronic low-grade inflammation.
  • Researchers explored whether the markers of inflammation IL-6, tumor necrosis factor alpha (TNF-α), and high-sensitivity C-reactive protein (hsCRP) can serve as predictive biomarkers for obesity-related cancers in patients recently diagnosed with T2D.
  • They identified patients with recent-onset T2D and no prior history of cancer participating in the ongoing Danish Centre...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Patient / Consumer, Provider
Achieving Value-Based Care Through the Payvider Model
208 million Americans are classified as obese or overweight, according to new study on 132 data sources
Epic's new interoperability push, explained
How 3 Health Systems Are Scaling Hybrid & Home-Based Models
CMS finalizes new kidney transplant model: 10 things to know

Share This Article